FY2024 EPS Estimates for Acelyrin Increased by HC Wainwright

Acelyrin, Inc. (NASDAQ:SLRN) – Research analysts at HC Wainwright raised their FY2024 EPS estimates for Acelyrin in a report released on Thursday, November 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($2.43) for the year, up from their previous forecast of ($3.35). HC Wainwright has a “Neutral” rating and a $8.00 price target on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.90) per share. HC Wainwright also issued estimates for Acelyrin’s Q4 2024 earnings at ($0.72) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.07) EPS and FY2028 earnings at ($1.30) EPS.

Several other research analysts have also recently issued reports on SLRN. Morgan Stanley lowered their price objective on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, August 19th. Wells Fargo & Company raised their price objective on shares of Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, October 16th. Finally, Piper Sandler lowered their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Acelyrin presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Acelyrin Trading Down 9.1 %

Shares of NASDAQ:SLRN opened at $4.69 on Monday. The company has a market cap of $470.55 million, a PE ratio of -1.91 and a beta of 1.98. The company’s 50 day moving average is $5.41 and its two-hundred day moving average is $5.02. Acelyrin has a 52 week low of $3.36 and a 52 week high of $9.20.

Institutional Investors Weigh In On Acelyrin

Several large investors have recently modified their holdings of the company. Blair William & Co. IL acquired a new stake in Acelyrin during the 1st quarter worth $936,000. Acadian Asset Management LLC purchased a new position in shares of Acelyrin during the second quarter worth about $590,000. Jacobs Levy Equity Management Inc. acquired a new position in Acelyrin in the 1st quarter valued at about $3,961,000. Almitas Capital LLC purchased a new stake in Acelyrin during the 2nd quarter valued at approximately $1,659,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Acelyrin during the 2nd quarter worth approximately $693,000. 87.31% of the stock is owned by institutional investors and hedge funds.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.